nodes	percent_of_prediction	percent_of_DWPC	metapath
Deferiprone—Nephropathy—Methotrexate—lymphatic system cancer	0.00549	0.00549	CcSEcCtD
Deferiprone—Furuncle—Methotrexate—lymphatic system cancer	0.00533	0.00533	CcSEcCtD
Deferiprone—Pancytopenia—Fludarabine—lymphatic system cancer	0.00526	0.00526	CcSEcCtD
Deferiprone—Neutropenia—Fludarabine—lymphatic system cancer	0.00517	0.00517	CcSEcCtD
Deferiprone—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00503	0.00503	CcSEcCtD
Deferiprone—Pneumonia—Fludarabine—lymphatic system cancer	0.00496	0.00496	CcSEcCtD
Deferiprone—Sepsis—Carmustine—lymphatic system cancer	0.0049	0.0049	CcSEcCtD
Deferiprone—Anaphylactic shock—Mechlorethamine—lymphatic system cancer	0.00486	0.00486	CcSEcCtD
Deferiprone—Arthritis—Bleomycin—lymphatic system cancer	0.00483	0.00483	CcSEcCtD
Deferiprone—Infection—Mechlorethamine—lymphatic system cancer	0.00482	0.00482	CcSEcCtD
Deferiprone—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00472	0.00472	CcSEcCtD
Deferiprone—Epistaxis—Fludarabine—lymphatic system cancer	0.00465	0.00465	CcSEcCtD
Deferiprone—Sepsis—Mitoxantrone—lymphatic system cancer	0.00455	0.00455	CcSEcCtD
Deferiprone—Chills—Teniposide—lymphatic system cancer	0.00452	0.00452	CcSEcCtD
Deferiprone—Pharyngitis—Fludarabine—lymphatic system cancer	0.0044	0.0044	CcSEcCtD
Deferiprone—Decreased appetite—Mechlorethamine—lymphatic system cancer	0.00422	0.00422	CcSEcCtD
Deferiprone—Diplopia—Carmustine—lymphatic system cancer	0.0041	0.0041	CcSEcCtD
Deferiprone—Chills—Fludarabine—lymphatic system cancer	0.00397	0.00397	CcSEcCtD
Deferiprone—Pain in extremity—Vincristine—lymphatic system cancer	0.00391	0.00391	CcSEcCtD
Deferiprone—Cardiac failure—Mitoxantrone—lymphatic system cancer	0.0039	0.0039	CcSEcCtD
Deferiprone—Malnutrition—Fludarabine—lymphatic system cancer	0.00386	0.00386	CcSEcCtD
Deferiprone—Pancytopenia—Bleomycin—lymphatic system cancer	0.00385	0.00385	CcSEcCtD
Deferiprone—Hypertension—Teniposide—lymphatic system cancer	0.00379	0.00379	CcSEcCtD
Deferiprone—Pneumonia—Bleomycin—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Deferiprone—Dehydration—Vincristine—lymphatic system cancer	0.00364	0.00364	CcSEcCtD
Deferiprone—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00358	0.00358	CcSEcCtD
Deferiprone—Infection—Teniposide—lymphatic system cancer	0.00356	0.00356	CcSEcCtD
Deferiprone—Dehydration—Mitoxantrone—lymphatic system cancer	0.00354	0.00354	CcSEcCtD
Deferiprone—Aspartate aminotransferase increased—Vincristine—lymphatic system cancer	0.00352	0.00352	CcSEcCtD
Deferiprone—Hyperhidrosis—Teniposide—lymphatic system cancer	0.00346	0.00346	CcSEcCtD
Deferiprone—Pruritus—Mechlorethamine—lymphatic system cancer	0.00344	0.00344	CcSEcCtD
Deferiprone—Aspartate aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00343	0.00343	CcSEcCtD
Deferiprone—Pancytopenia—Carmustine—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Deferiprone—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00336	0.00336	CcSEcCtD
Deferiprone—Hypotension—Teniposide—lymphatic system cancer	0.00335	0.00335	CcSEcCtD
Deferiprone—Convulsion—Fludarabine—lymphatic system cancer	0.00334	0.00334	CcSEcCtD
Deferiprone—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00332	0.00332	CcSEcCtD
Deferiprone—Neutropenia—Carmustine—lymphatic system cancer	0.00331	0.00331	CcSEcCtD
Deferiprone—Arthralgia—Fludarabine—lymphatic system cancer	0.00328	0.00328	CcSEcCtD
Deferiprone—Discomfort—Fludarabine—lymphatic system cancer	0.00324	0.00324	CcSEcCtD
Deferiprone—Pancytopenia—Vincristine—lymphatic system cancer	0.00321	0.00321	CcSEcCtD
Deferiprone—Pneumonia—Carmustine—lymphatic system cancer	0.00318	0.00318	CcSEcCtD
Deferiprone—Neutropenia—Vincristine—lymphatic system cancer	0.00316	0.00316	CcSEcCtD
Deferiprone—Anaphylactic shock—Fludarabine—lymphatic system cancer	0.00315	0.00315	CcSEcCtD
Deferiprone—Pancytopenia—Mitoxantrone—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Deferiprone—Infection—Fludarabine—lymphatic system cancer	0.00313	0.00313	CcSEcCtD
Deferiprone—Decreased appetite—Teniposide—lymphatic system cancer	0.00311	0.00311	CcSEcCtD
Deferiprone—Vomiting—Mechlorethamine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Deferiprone—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Deferiprone—Photosensitivity reaction—Vincristine—lymphatic system cancer	0.00309	0.00309	CcSEcCtD
Deferiprone—Neutropenia—Mitoxantrone—lymphatic system cancer	0.00308	0.00308	CcSEcCtD
Deferiprone—Rash—Mechlorethamine—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Deferiprone—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00306	0.00306	CcSEcCtD
Deferiprone—Hyperhidrosis—Fludarabine—lymphatic system cancer	0.00304	0.00304	CcSEcCtD
Deferiprone—Pneumonia—Vincristine—lymphatic system cancer	0.00303	0.00303	CcSEcCtD
Deferiprone—Weight increased—Mitoxantrone—lymphatic system cancer	0.003	0.003	CcSEcCtD
Deferiprone—Pneumonia—Mitoxantrone—lymphatic system cancer	0.00295	0.00295	CcSEcCtD
Deferiprone—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00293	0.00293	CcSEcCtD
Deferiprone—Chills—Bleomycin—lymphatic system cancer	0.00291	0.00291	CcSEcCtD
Deferiprone—Nausea—Mechlorethamine—lymphatic system cancer	0.00288	0.00288	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Fludarabine—lymphatic system cancer	0.00287	0.00287	CcSEcCtD
Deferiprone—Jaundice—Mitoxantrone—lymphatic system cancer	0.00286	0.00286	CcSEcCtD
Deferiprone—Urticaria—Teniposide—lymphatic system cancer	0.00284	0.00284	CcSEcCtD
Deferiprone—Abdominal pain—Teniposide—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Deferiprone—Body temperature increased—Teniposide—lymphatic system cancer	0.00283	0.00283	CcSEcCtD
Deferiprone—Oedema peripheral—Carmustine—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Deferiprone—Connective tissue disorder—Carmustine—lymphatic system cancer	0.00279	0.00279	CcSEcCtD
Deferiprone—Dyspepsia—Fludarabine—lymphatic system cancer	0.00277	0.00277	CcSEcCtD
Deferiprone—Agranulocytosis—Mitoxantrone—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Deferiprone—Decreased appetite—Fludarabine—lymphatic system cancer	0.00274	0.00274	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00272	0.00272	CcSEcCtD
Deferiprone—Fatigue—Fludarabine—lymphatic system cancer	0.00271	0.00271	CcSEcCtD
Deferiprone—Pain—Fludarabine—lymphatic system cancer	0.00269	0.00269	CcSEcCtD
Deferiprone—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00267	0.00267	CcSEcCtD
Deferiprone—Connective tissue disorder—Vincristine—lymphatic system cancer	0.00266	0.00266	CcSEcCtD
Deferiprone—Urethral disorder—Vincristine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Deferiprone—Eye disorder—Carmustine—lymphatic system cancer	0.00265	0.00265	CcSEcCtD
Deferiprone—Hypersensitivity—Teniposide—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Deferiprone—Hepatitis—Mitoxantrone—lymphatic system cancer	0.00264	0.00264	CcSEcCtD
Deferiprone—Pharyngitis—Mitoxantrone—lymphatic system cancer	0.00262	0.00262	CcSEcCtD
Deferiprone—Pulmonary embolism—Methotrexate—lymphatic system cancer	0.00261	0.00261	CcSEcCtD
Deferiprone—Asthenia—Teniposide—lymphatic system cancer	0.00257	0.00257	CcSEcCtD
Deferiprone—Pruritus—Teniposide—lymphatic system cancer	0.00253	0.00253	CcSEcCtD
Deferiprone—Cardiac disorder—Vincristine—lymphatic system cancer	0.00251	0.00251	CcSEcCtD
Deferiprone—Body temperature increased—Fludarabine—lymphatic system cancer	0.00249	0.00249	CcSEcCtD
Deferiprone—Mental disorder—Carmustine—lymphatic system cancer	0.00248	0.00248	CcSEcCtD
Deferiprone—Malnutrition—Carmustine—lymphatic system cancer	0.00247	0.00247	CcSEcCtD
Deferiprone—Angiopathy—Vincristine—lymphatic system cancer	0.00246	0.00246	CcSEcCtD
Deferiprone—Diarrhoea—Teniposide—lymphatic system cancer	0.00245	0.00245	CcSEcCtD
Deferiprone—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00244	0.00244	CcSEcCtD
Deferiprone—Back pain—Carmustine—lymphatic system cancer	0.00239	0.00239	CcSEcCtD
Deferiprone—Discomfort—Bleomycin—lymphatic system cancer	0.00238	0.00238	CcSEcCtD
Deferiprone—Mental disorder—Vincristine—lymphatic system cancer	0.00237	0.00237	CcSEcCtD
Deferiprone—Chills—Mitoxantrone—lymphatic system cancer	0.00236	0.00236	CcSEcCtD
Deferiprone—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00232	0.00232	CcSEcCtD
Deferiprone—Anaphylactic shock—Bleomycin—lymphatic system cancer	0.00231	0.00231	CcSEcCtD
Deferiprone—Infection—Bleomycin—lymphatic system cancer	0.00229	0.00229	CcSEcCtD
Deferiprone—Back pain—Vincristine—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Deferiprone—Vomiting—Teniposide—lymphatic system cancer	0.00228	0.00228	CcSEcCtD
Deferiprone—Sepsis—Methotrexate—lymphatic system cancer	0.00227	0.00227	CcSEcCtD
Deferiprone—Asthenia—Fludarabine—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Deferiprone—Rash—Teniposide—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Deferiprone—Dermatitis—Teniposide—lymphatic system cancer	0.00226	0.00226	CcSEcCtD
Deferiprone—Headache—Teniposide—lymphatic system cancer	0.00224	0.00224	CcSEcCtD
Deferiprone—Pruritus—Fludarabine—lymphatic system cancer	0.00223	0.00223	CcSEcCtD
Deferiprone—Back pain—Mitoxantrone—lymphatic system cancer	0.00222	0.00222	CcSEcCtD
Deferiprone—Hypotension—Bleomycin—lymphatic system cancer	0.00216	0.00216	CcSEcCtD
Deferiprone—Diarrhoea—Fludarabine—lymphatic system cancer	0.00215	0.00215	CcSEcCtD
Deferiprone—Convulsion—Carmustine—lymphatic system cancer	0.00214	0.00214	CcSEcCtD
Deferiprone—Hypertension—Carmustine—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Deferiprone—Nausea—Teniposide—lymphatic system cancer	0.00213	0.00213	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	0.0021	0.0021	CcSEcCtD
Deferiprone—Convulsion—Vincristine—lymphatic system cancer	0.00204	0.00204	CcSEcCtD
Deferiprone—Hypertension—Vincristine—lymphatic system cancer	0.00203	0.00203	CcSEcCtD
Deferiprone—Decreased appetite—Bleomycin—lymphatic system cancer	0.00201	0.00201	CcSEcCtD
Deferiprone—Infection—Carmustine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Deferiprone—Vomiting—Fludarabine—lymphatic system cancer	0.002	0.002	CcSEcCtD
Deferiprone—Convulsion—Mitoxantrone—lymphatic system cancer	0.00199	0.00199	CcSEcCtD
Deferiprone—Rash—Fludarabine—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Deferiprone—Dermatitis—Fludarabine—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Deferiprone—Hypertension—Mitoxantrone—lymphatic system cancer	0.00198	0.00198	CcSEcCtD
Deferiprone—Pain—Bleomycin—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Deferiprone—Headache—Fludarabine—lymphatic system cancer	0.00197	0.00197	CcSEcCtD
Deferiprone—Arthralgia—Mitoxantrone—lymphatic system cancer	0.00195	0.00195	CcSEcCtD
Deferiprone—Discomfort—Mitoxantrone—lymphatic system cancer	0.00193	0.00193	CcSEcCtD
Deferiprone—Anaphylactic shock—Vincristine—lymphatic system cancer	0.00192	0.00192	CcSEcCtD
Deferiprone—Infection—Vincristine—lymphatic system cancer	0.00191	0.00191	CcSEcCtD
Deferiprone—Osteoarthritis—Methotrexate—lymphatic system cancer	0.0019	0.0019	CcSEcCtD
Deferiprone—Nervous system disorder—Vincristine—lymphatic system cancer	0.00189	0.00189	CcSEcCtD
Deferiprone—Hypotension—Carmustine—lymphatic system cancer	0.00188	0.00188	CcSEcCtD
Deferiprone—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Deferiprone—Nausea—Fludarabine—lymphatic system cancer	0.00187	0.00187	CcSEcCtD
Deferiprone—Infection—Mitoxantrone—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Deferiprone—Hyperhidrosis—Vincristine—lymphatic system cancer	0.00186	0.00186	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Deferiprone—Urticaria—Bleomycin—lymphatic system cancer	0.00183	0.00183	CcSEcCtD
Deferiprone—Body temperature increased—Bleomycin—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Deferiprone—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00182	0.00182	CcSEcCtD
Deferiprone—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	0.00181	0.00181	CcSEcCtD
Deferiprone—Hypotension—Vincristine—lymphatic system cancer	0.0018	0.0018	CcSEcCtD
Deferiprone—Somnolence—Carmustine—lymphatic system cancer	0.00179	0.00179	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Deferiprone—Decreased appetite—Carmustine—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Deferiprone—Hypotension—Mitoxantrone—lymphatic system cancer	0.00175	0.00175	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00174	0.00174	CcSEcCtD
Deferiprone—Pain—Carmustine—lymphatic system cancer	0.00172	0.00172	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	0.00171	0.00171	CcSEcCtD
Deferiprone—Hypersensitivity—Bleomycin—lymphatic system cancer	0.0017	0.0017	CcSEcCtD
Deferiprone—Decreased appetite—Vincristine—lymphatic system cancer	0.00167	0.00167	CcSEcCtD
Deferiprone—Somnolence—Mitoxantrone—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Deferiprone—Fatigue—Vincristine—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Deferiprone—Asthenia—Bleomycin—lymphatic system cancer	0.00166	0.00166	CcSEcCtD
Deferiprone—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Deferiprone—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00165	0.00165	CcSEcCtD
Deferiprone—Pain—Vincristine—lymphatic system cancer	0.00164	0.00164	CcSEcCtD
Deferiprone—Pruritus—Bleomycin—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Deferiprone—Decreased appetite—Mitoxantrone—lymphatic system cancer	0.00163	0.00163	CcSEcCtD
Deferiprone—Fatigue—Mitoxantrone—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Deferiprone—Pancreatitis—Methotrexate—lymphatic system cancer	0.00161	0.00161	CcSEcCtD
Deferiprone—Pain—Mitoxantrone—lymphatic system cancer	0.0016	0.0016	CcSEcCtD
Deferiprone—Body temperature increased—Carmustine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Deferiprone—Abdominal pain—Carmustine—lymphatic system cancer	0.00159	0.00159	CcSEcCtD
Deferiprone—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00157	0.00157	CcSEcCtD
Deferiprone—Pancytopenia—Methotrexate—lymphatic system cancer	0.00156	0.00156	CcSEcCtD
Deferiprone—Neutropenia—Methotrexate—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Deferiprone—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00153	0.00153	CcSEcCtD
Deferiprone—Body temperature increased—Vincristine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Deferiprone—Abdominal pain—Vincristine—lymphatic system cancer	0.00152	0.00152	CcSEcCtD
Deferiprone—Photosensitivity reaction—Methotrexate—lymphatic system cancer	0.0015	0.0015	CcSEcCtD
Deferiprone—Urticaria—Mitoxantrone—lymphatic system cancer	0.00149	0.00149	CcSEcCtD
Deferiprone—Hypersensitivity—Carmustine—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Deferiprone—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Deferiprone—Body temperature increased—Mitoxantrone—lymphatic system cancer	0.00148	0.00148	CcSEcCtD
Deferiprone—Pneumonia—Methotrexate—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Deferiprone—Vomiting—Bleomycin—lymphatic system cancer	0.00147	0.00147	CcSEcCtD
Deferiprone—Infestation NOS—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Deferiprone—Infestation—Methotrexate—lymphatic system cancer	0.00146	0.00146	CcSEcCtD
Deferiprone—Rash—Bleomycin—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Deferiprone—Dermatitis—Bleomycin—lymphatic system cancer	0.00145	0.00145	CcSEcCtD
Deferiprone—Asthenia—Carmustine—lymphatic system cancer	0.00144	0.00144	CcSEcCtD
Deferiprone—Hypersensitivity—Vincristine—lymphatic system cancer	0.00142	0.00142	CcSEcCtD
Deferiprone—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Deferiprone—Epistaxis—Methotrexate—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Deferiprone—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Deferiprone—Asthenia—Vincristine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Deferiprone—Diarrhoea—Carmustine—lymphatic system cancer	0.00138	0.00138	CcSEcCtD
Deferiprone—Nausea—Bleomycin—lymphatic system cancer	0.00137	0.00137	CcSEcCtD
Deferiprone—Agranulocytosis—Methotrexate—lymphatic system cancer	0.00136	0.00136	CcSEcCtD
Deferiprone—Asthenia—Mitoxantrone—lymphatic system cancer	0.00134	0.00134	CcSEcCtD
Deferiprone—Diarrhoea—Vincristine—lymphatic system cancer	0.00132	0.00132	CcSEcCtD
Deferiprone—Hepatitis—Methotrexate—lymphatic system cancer	0.00131	0.00131	CcSEcCtD
Deferiprone—Pharyngitis—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Deferiprone—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.0013	0.0013	CcSEcCtD
Deferiprone—Urethral disorder—Methotrexate—lymphatic system cancer	0.00129	0.00129	CcSEcCtD
Deferiprone—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Deferiprone—Vomiting—Carmustine—lymphatic system cancer	0.00128	0.00128	CcSEcCtD
Deferiprone—Rash—Carmustine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Deferiprone—Dermatitis—Carmustine—lymphatic system cancer	0.00127	0.00127	CcSEcCtD
Deferiprone—Headache—Carmustine—lymphatic system cancer	0.00126	0.00126	CcSEcCtD
Deferiprone—Eye disorder—Methotrexate—lymphatic system cancer	0.00123	0.00123	CcSEcCtD
Deferiprone—Vomiting—Vincristine—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Deferiprone—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00122	0.00122	CcSEcCtD
Deferiprone—Rash—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Deferiprone—Dermatitis—Vincristine—lymphatic system cancer	0.00121	0.00121	CcSEcCtD
Deferiprone—Headache—Vincristine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Deferiprone—Nausea—Carmustine—lymphatic system cancer	0.0012	0.0012	CcSEcCtD
Deferiprone—Angiopathy—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Deferiprone—Vomiting—Mitoxantrone—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Deferiprone—Immune system disorder—Methotrexate—lymphatic system cancer	0.00119	0.00119	CcSEcCtD
Deferiprone—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Deferiprone—Rash—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Deferiprone—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Deferiprone—Chills—Methotrexate—lymphatic system cancer	0.00118	0.00118	CcSEcCtD
Deferiprone—Headache—Mitoxantrone—lymphatic system cancer	0.00117	0.00117	CcSEcCtD
Deferiprone—Mental disorder—Methotrexate—lymphatic system cancer	0.00115	0.00115	CcSEcCtD
Deferiprone—Malnutrition—Methotrexate—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Deferiprone—Nausea—Vincristine—lymphatic system cancer	0.00114	0.00114	CcSEcCtD
Deferiprone—Nausea—Mitoxantrone—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Deferiprone—Back pain—Methotrexate—lymphatic system cancer	0.00111	0.00111	CcSEcCtD
Deferiprone—Convulsion—Methotrexate—lymphatic system cancer	0.00099	0.00099	CcSEcCtD
Deferiprone—Arthralgia—Methotrexate—lymphatic system cancer	0.000973	0.000973	CcSEcCtD
Deferiprone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000966	0.000966	CcSEcCtD
Deferiprone—Discomfort—Methotrexate—lymphatic system cancer	0.000961	0.000961	CcSEcCtD
Deferiprone—Anaphylactic shock—Methotrexate—lymphatic system cancer	0.000933	0.000933	CcSEcCtD
Deferiprone—Infection—Methotrexate—lymphatic system cancer	0.000927	0.000927	CcSEcCtD
Deferiprone—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000915	0.000915	CcSEcCtD
Deferiprone—Skin disorder—Methotrexate—lymphatic system cancer	0.000906	0.000906	CcSEcCtD
Deferiprone—Hyperhidrosis—Methotrexate—lymphatic system cancer	0.000902	0.000902	CcSEcCtD
Deferiprone—Hypotension—Methotrexate—lymphatic system cancer	0.000872	0.000872	CcSEcCtD
Deferiprone—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	0.00085	0.00085	CcSEcCtD
Deferiprone—Somnolence—Methotrexate—lymphatic system cancer	0.000829	0.000829	CcSEcCtD
Deferiprone—Dyspepsia—Methotrexate—lymphatic system cancer	0.000821	0.000821	CcSEcCtD
Deferiprone—Decreased appetite—Methotrexate—lymphatic system cancer	0.000811	0.000811	CcSEcCtD
Deferiprone—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000805	0.000805	CcSEcCtD
Deferiprone—Fatigue—Methotrexate—lymphatic system cancer	0.000804	0.000804	CcSEcCtD
Deferiprone—Pain—Methotrexate—lymphatic system cancer	0.000798	0.000798	CcSEcCtD
Deferiprone—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000763	0.000763	CcSEcCtD
Deferiprone—Urticaria—Methotrexate—lymphatic system cancer	0.000741	0.000741	CcSEcCtD
Deferiprone—Body temperature increased—Methotrexate—lymphatic system cancer	0.000737	0.000737	CcSEcCtD
Deferiprone—Abdominal pain—Methotrexate—lymphatic system cancer	0.000737	0.000737	CcSEcCtD
Deferiprone—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000687	0.000687	CcSEcCtD
Deferiprone—Asthenia—Methotrexate—lymphatic system cancer	0.000669	0.000669	CcSEcCtD
Deferiprone—Pruritus—Methotrexate—lymphatic system cancer	0.00066	0.00066	CcSEcCtD
Deferiprone—Diarrhoea—Methotrexate—lymphatic system cancer	0.000638	0.000638	CcSEcCtD
Deferiprone—Vomiting—Methotrexate—lymphatic system cancer	0.000593	0.000593	CcSEcCtD
Deferiprone—Rash—Methotrexate—lymphatic system cancer	0.000588	0.000588	CcSEcCtD
Deferiprone—Dermatitis—Methotrexate—lymphatic system cancer	0.000588	0.000588	CcSEcCtD
Deferiprone—Headache—Methotrexate—lymphatic system cancer	0.000584	0.000584	CcSEcCtD
Deferiprone—Nausea—Methotrexate—lymphatic system cancer	0.000554	0.000554	CcSEcCtD
